Exogenous L-DOPA appeared to protect against the development of wet age-related macular degeneration (AMD) in multiple cohorts of patients, according to a retrospective study published in the American Journal of Medicine.1

Researchers analyzed medical records to compare the incidence of AMD in patients taking L-DOPA and those not taking L-DOPA. Three cohorts of patients were analyzed: two separate cohorts from the Marshfield Clinic in Wisconsin (n = 17 000 and n = 20 000) and one from the Truven MarketScan databases (n = 87 million).

For patients not taking L-DOPA, the average age of AMD diagnosis was approximately 71.3 years in all three groups. This was a significantly earlier onset than patients taking L-DOPA, who were diagnosed with AMD at an average age of 79.4 years.

1. Brilliant MH, Viziri K, Connor TB, et al. Mining retrospective data for virtual prospective drug repurposing: L-DOPA and age-related macular degeneration [published online ahead of print October 30, 2015]. Am J Med.


Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Scott Krzywonos

Janet Burk

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.